Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4368 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.71 |
drug3391 | Problem-solving and relationship improvement intervention. Wiki | 0.71 |
drug1038 | Cognitive and behavioral intervention. Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D006929 | Hyperaldosteronism NIH | 0.71 |
D054559 | Hyperphosphatemia NIH | 0.71 |
D004314 | Down Syndrome NIH | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D007008 | Hypokalemia NIH | 0.71 |
D008595 | Menorrhagia NIH | 0.71 |
D000309 | Adrenal Insufficiency NIH | 0.71 |
D006965 | Hyperplasia NIH | 0.50 |
D014552 | Urinary Tract Infections NIH | 0.50 |
D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.41 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.35 |
D006470 | Hemorrhage NIH | 0.35 |
D020141 | Hemostatic Disorders NIH | 0.18 |
D001778 | Blood Coagulation Disorders NIH | 0.18 |
D006973 | Hypertension NIH | 0.14 |
D004194 | Disease NIH | 0.11 |
D013577 | Syndrome NIH | 0.06 |
D003141 | Communicable Diseases NIH | 0.05 |
D007239 | Infection NIH | 0.03 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002905 | Hyperphosphatemia HPO | 0.71 |
HP:0000132 | Menorrhagia HPO | 0.71 |
HP:0002900 | Hypokalemia HPO | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000846 | Adrenal insufficiency HPO | 0.71 |
HP:0000859 | Hyperaldosteronism HPO | 0.71 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.35 |
HP:0001928 | Abnormality of coagulation HPO | 0.18 |
HP:0000822 | Hypertension HPO | 0.14 |
Navigate: Correlations HPO
There are 2 clinical trials
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
The purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature at 36 weeks Postmenstrual Age (PMA), as compared to babies born premature who receive standard neonatal care alone.
Description: Dose escalation of AT-100 up to the maximum feasible dose in order to assess safety and tolerability
Measure: Phase 1b: Determining the highest-tolerated & safety-tested AT-100 dose Time: From time of initial AT-100 dosing until end of the dosing period, up to 7 daysDescription: Days on mechanical ventilation.
Measure: Phase 2: Reduction in time on mechanical ventilation Time: From birth to 36 Weeks Postmenstrual Age (PMA)Description: Incidence of BPD or death.
Measure: BPD or death Time: At 36 Weeks PMADescription: Days on mechanical ventilation.
Measure: Long term reduction in time on mechanical ventilation Time: From birth to 1 year Corrected Age (CA)Description: Days on respiratory oxygen support.
Measure: Long term reduction in time on respiratory support Time: From birth to 1 year Corrected Age (CA)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports